DEAL TALK: Juno Therapeutics soared 50.9 percent after the Wall Street Journal reported that biotech drugmaker Celgene might buy it. Juno is one of several companies developing therapies that involve genetically engineering patients' blood cells to fight cancer. Juno rose $23.23 to $68.83.…
News
- Tech, health care companies help lift US stocks higher
- How SA's venture capital pipeline flowed to finish 2017
Dominion Aesthetic Technologies is a San Antonio-based biotechnology startup founded in 2015 and focused on commercializing new plastic and reconstructive surgery techniques. The company raised $1.6 million from MagnaSci Ventures, a Houston-based venture capital group. Dominion Aesthetic…
- GenCure Opens BioManufacturing Center for Large-Scale Production of Adult Stem Cells to ...
In 2016, BioBridge Global and GenCure led a team including the U.S. Army Institute of Surgical Research and biotech firms Rooster Bio (based in Maryland) and StemBioSys (based in San Antonio), which was awarded a $7.8-million contract from the Medical Technology Enterprise Consortium (MTEC)…
- San Antonio's Bioscience-Medicine Industry Could Help Solve City's Top Health Problems
Working to leverage the city's biomedical assets, like locally-based research and hospitals, the plan aims to fuel economic growth and harness San Antonio's strengths to become a global healthcare resource. What is the impact of healthcare and bioscience on San Antonio's economy? How can the…
- Celgene, Dave & Buster's slide while Kohl's and Crocs rise
The biotech drugmaker said it will buy Impact Biomedicines for $1.1 billion, with up to $5.9 billion in other potential payments. NuVasive Inc., down $5.45 to $55.56. The spinal device maker gave a disappointing forecast for 2018. Crocs Inc., up $1.03 to $13.23. The shoe company raised its sales…